Market Overview

Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO)

Share:

Glancy
Prongay & Murray LLP
("GPM") reminds investors of the January
16, 2018
deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased Meridian Bioscience,
Inc. ("Meridian Bioscience" or the "Company") (NASDAQ: VIVO)
securities between March 25, 2016 and July 13, 2017, inclusive
(the "Class Period") Meridian Bioscience investors have until January
16, 2018
 to file a lead plaintiff motion. To obtain information or
participate in the class action, please visit the Meridian Bioscience
page on our website at www.glancylaw.com/case/meridian-bioscience-inc.

Investors suffering losses on their Meridian Bioscience investments are
encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

On May 17, 2017, the U.S. Food and Drug Administration ("FDA") issued a
warning to Meridian that lead tests conducted by the Company's
subsidiary, Magellan Diagnostics, may be incorrect. According to the
FDA, tests performed on blood drawn from a vein has led to "results that
are lower than the actual level of lead in the blood." The FDA has
recommended discontinuation of Magellan when testing with venous blood
samples. On this news, Meridian shares fell over 9% on May 17, 2017.
Then on May 25, 2017, Meridian's Magellan Diagnostics announced a Class
1 recall of its LeadCare Plus and Ultra Testing Systems due to
"inaccurate test results."

On June 6, 2017 Meridian's Magellan Diagnostics subsidiary expanded the
recall to incorporate the Company's LeadCare and LeadCare II testing
systems. On this news, shares of Meridian traded as low as $13.40 per
share.

The complaint alleges that throughout the class period Defendants made
materially false and/or misleading statements and/or failed to disclose
that: (1) Defendant's lead tests provide inaccurate results; and (2)
consequently, Meridian's public statements were materially false and
misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Meridian Bioscience during the Class Period
you may move the Court no later than January 16, 2018 to ask
the Court to appoint you as lead. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice
or take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley
Portnoy
, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los
Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!